Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.
Inherited variants in the DPYD gene can increase the risk of life-threatening toxicity from fluoropyrimidine-based chemotherapies, yet screening remains inconsistent across care settings.
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
A study found that circulating tumor DNA testing detected residual disease signals missed by conventional prognostic measures in patients with breast cancer.
Roche has launched the cobas eplex RP3 panel for CE-markets, enabling simultaneous detection of up to 25 respiratory pathogens with customizable configurations, according to the company.
The approval makes MyChoice CDx the sole FDA-approved test in the US to identify HRD-positive patients eligible for niraparib maintenance therapy.
Researchers at JAX and MIT have developed a microneedle patch that samples immune cells from skin within hours, providing a noninvasive alternative to blood draws and biopsies.
The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Researchers at UC San Diego have developed the MAPI score, a blood test using five standard lab values to distinguish alcohol-related liver injury from metabolic causes, according to a study in Gastroenterology.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Research in bone marrow transplant patients with blood cancers and febrile neutropenia suggests the host-response test may help identify infection in high-risk populations.